Novartis Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrates unprecedented efficacy in pediatric patients with BRAF V600 low-grade gliomas in Phase II/III study

Treatment with targeted therapies Tafinlar + Mekinist resulted in 47% ORR versus chemotherapy (11%) and reduced risk of progression or death by 69%, showing...

Related Keywords

United States ,America ,American ,Julie Masow ,Sloan Simpson ,Acta Neuropathol ,Dan Connelly ,Prnewswire Novartis ,Anticancer Fund ,American Society Of Clinical Oncology ,Twitter ,Novartis Oncology Communications ,Novartis External Communications ,Novartis ,Exchange Commission ,Nj Novartis Pharmaceuticals Corporation ,Novartis Pharmaceuticals Corp ,Safety Information ,Prescribing Information ,East Hanover ,Pharmaceuticals Corporation ,Clinical Oncology ,Low Grade Glioma ,Glioma Guide ,Neuropathol Exp ,Top Microbiol ,Novartis Pharmaceuticals ,Oncology Communications ,Novartis Us ,Medical Pharmaceuticals ,Health Care Amp Hospitals ,Biotechnology ,Pharmaceuticals ,Clinical Trials Amp Medical Discoveries ,